Navigation Links
Publication Confirms that EpCAM, the Target for Two of Micromet's,Product Candidates, Is Overexpressed on Cancer Stem Cells of,Certain Cancers

BETHESDA, Md., June 26, 2007 /PRNewswire-FirstCall/ -- Micromet, Inc. , a biopharmaceutical company focusing on the development of novel, proprietary antibody-based products for cancer, inflammatory and autoimmune diseases, announced that a study published recently in the Proceedings of the National Academy of Sciences (1) supports the findings of several other studies that EpCAM (CD326), which is used as the target for Micromet's product candidates adecatumumab (MT201) and MT110, may be suitable as a target for eradication of so called "cancer stem cells" (CSCs). The other studies showed that CSCs from colon (2), breast (3), pancreatic (4) and prostate (5) cancers all express high levels of EpCAM, which, according to these studies, makes these cells particularly capable of causing tumors.

CSCs constitute a small percentage of tumor cells that have the potential to self-renew and to permanently repopulate a tumor with new cancer cells. CSCs appear to be resistant to various chemotherapies, which may be one of the key reasons why most current therapies cannot cure cancer through elimination of all tumor cells (6). Micromet scientists believe that the findings of EpCAM expression by CSCs in many cancers and of EpCAM being a frequently and highly expressed tumor-associated antigen (7, 8), supports Micromet's use of EpCAM for targeted therapeutics.

EpCAM is the target for Micromet's clinical-stage product candidate adecatumumab (MT201), a fully human monoclonal antibody being co-developed with Merck Serono. In addition, Micromet's BiTE(R) product candidate MT110, an anti-EpCAM/CD3-bispecific antibody construct, is currently in late preclinical development. Both product candidates are designed to recognize EpCAM- expressing cancer cells and to instruct cytotoxic cells of the immune system to eliminate such cancer cells.

"The 'seek and destroy' mechanism of our EpCAM-directed therapeutic drug can
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Response Genetics Announces Publication of a Phase III Clinical Trial Demonstrating That Low Levels of ERCC-1 Help to Predict Likelihood of Response to Cisplatin-Based Therapy in Lung Cancer
2. DOR BioPharma Announces Publication Describing Results of Its Multivalent Botulinum Toxin Vaccine BT-VACC
3. Publication on Pixantrone Preclinical Studies Demonstrates Reduced Cardiotoxicity Compared to Equiactive Doses of Doxorubicin and Mitoxantrone
4. Neurologix Announces Publication of Landmark Gene Therapy Study Demonstrating Safety and Statistically Significant Improvement in Patients With Advanced Parkinsons Disease
5. Nuvelo Announces Publication of Phase 2 rNAPc2 Study Results in Journal of American College of Cardiology
6. Critical Therapeutics Announces the Publication of Data for ZyfloCR (Zileuton) Extended-Release Tablets in the Journal of Asthma
7. Nuvelo Announces Publication of Preclinical Study Results Demonstrating the Potential of NTB-A as a New Target for Leukemia and Lymphomas
8. Thallion Announces Publication of ECO-4601 Phase I/II Clinical Data at ASCO
9. Cytogen Reports Publication Validating the Utility of its Proprietary ProChart Database
10. Independent Publication Confirms Growing Therapeutic Challenge of T315I Mutation in Patients with CML, Notes ChemGenex
11. Independent Publication Confirms Growing Therapeutic Challenge of T315I Mutation in Patients with CML, Notes ChemGenex
Post Your Comments:
(Date:10/31/2014)... LONDON , October 31, 2014 ... Nanosphere Inc. (NASDAQ: NSPH ), Isis Pharmaceuticals ... (NASDAQ: HALO ), ACADIA Pharmaceuticals Inc. (NASDAQ: ... SNTA). Free research on these five companies can be ... October 30, 2014, the NASDAQ Composite ended at 4,566.14, ...
(Date:10/31/2014)... BARCELONA , October 31, 2014 ... infringe two Australian patents of B. Braun Melsungen AG (B. ... Australia safety IV catheters manufactured by Poly Medicure ... Australia proceeding number VID 463 of ... In the detailed judgment, Multigate was found to have ...
(Date:10/31/2014)...  Isis Pharmaceuticals, Inc. (NASDAQ: ISIS ) ... Isis Pharmaceuticals, Third Quarter 2014 Financial Results and Highlights ... a.m. ET / 8:30 a.m. PTWhere: , ... log onto our website listed above. If you are ... of the webcast will be available for a limited ...
Breaking Medicine Technology:Momentum Indicators for Biotech Stocks -- Nanosphere, Isis Pharma, Halozyme Therapeutics, ACADIA Pharma, and Synta Pharma 2Momentum Indicators for Biotech Stocks -- Nanosphere, Isis Pharma, Halozyme Therapeutics, ACADIA Pharma, and Synta Pharma 3Momentum Indicators for Biotech Stocks -- Nanosphere, Isis Pharma, Halozyme Therapeutics, ACADIA Pharma, and Synta Pharma 4Momentum Indicators for Biotech Stocks -- Nanosphere, Isis Pharma, Halozyme Therapeutics, ACADIA Pharma, and Synta Pharma 5B. Braun Wins Patent Disputes Against Poly Medicure Ltd's Australian Distributor Multigate Medical Devices Pty. Ltd. and Spanish Distributor Dextromédica S. L. 2Webcast Alert: Isis Pharmaceuticals' Third Quarter 2014 Financial Results Conference Call 2Webcast Alert: Isis Pharmaceuticals' Third Quarter 2014 Financial Results Conference Call 3
(Date:10/31/2014)... central to life. The last stage, when two daughter ... the dawn of cell biology in the Victorian era. ... to study this final step, when the dividing cell ... name given to this process by those early biologists, ... of a highly active and organized series of events. ...
(Date:10/31/2014)... The Memory Healer review published by DailyGossip.org ... whose father suffered from Alzheimer's disease. , In fact, ... his father's disease. His father pointed a gun and shot ... when the author of this method understood that he needed ... Memory Healer program is based on years of research. The ...
(Date:10/31/2014)... With all the preparations families carry ... they may overlook one critical area – the potential ... school performance and even behavior. Typical children’s vision screenings ... progressive vision problems, and to address this challenge, Dr. ... initiative: The Awesome Eyes Student Vision Program. , ...
(Date:10/31/2014)... increases the risk of certain types of breast cancer ... studies show. One study of more than 3,200 ... risk for estrogen receptor-negative and progesterone receptor-positive breast tumors ... long time for white women, but now we are ... John, a senior research scientist at the Cancer Prevention ...
(Date:10/31/2014)... Santa Barbara, CA (PRWEB) October 31, 2014 ... for holiday shoppers to find affordable but tasteful gifts for ... special 22nd Annual Early Bird Gift Giving Special , ... percent off when they purchase Wine Club Gift membership. ... to take advantage of this special. Besides offering discounts, Gold ...
Breaking Medicine News(10 mins):Health News:Cell division, minus the cells 2Health News:Cell division, minus the cells 3Health News:"Memory Healer" Review Reveals a New Natural Remedy Guide for Managing Memory Loss 2Health News:New School Vision Initiative Announced by Dr. Rosenak’s Optical Options; Program Aims to Help Recognize Unseen Vision Problems That Impact School Success 2Health News:New School Vision Initiative Announced by Dr. Rosenak’s Optical Options; Program Aims to Help Recognize Unseen Vision Problems That Impact School Success 3Health News:Study Confirms Obesity-Breast Cancer Link for Blacks, Hispanics 2Health News:Gold Medal Wine Club now offering Early Bird Gift Giving Special for Holidays 2
... Department of Emergency Medicine has received a two-year, $150,000 ... the implementation of electronic health records in a suburban ... work of Michael Ward, MD, an assistant professor at ... year focusing on simulation modeling in operations research, working ...
... , TUESDAY, June 7 (HealthDay News) -- Imaging ... a detrimental effect on the brain, according to a new ... of the drug caused a decrease in the number of ... bodily functions, including concentration, movement coordination, pleasure, pain tolerance, memory ...
... , TUESDAY, June 7 (HealthDay News) -- People ... do relatively few surgeries are at greater risk for serious ... were more common among patients at hospitals with low surgical ... according to the study, published online June 7 in ...
... sounds, smells and events: far too much for us to ... be snagged by something startling, such as a slamming door, ... to us right then, such as locating our child among ... know that people are hard-wired to seek out and pay ...
... (HealthDay News) -- Being in a serious relationship is not ... new research suggests. In fact, a study by researchers ... times more likely to have unprotected sex than casual partners. ... nearly 70 percent of all new HIV/AIDS diagnoses among adolescents ...
... U.S. Department of Agriculture (USDA)-funded studies of mammary gland ... interest may aid breast cancer research. In an early ... C. M. Simmen of the Arkansas Children,s Nutrition Center (ACNC) ... rat mammary gland health were improved in the offspring (pups) ...
Cached Medicine News:Health News:Using simulation to model the implementation of electronic health records 2Health News:Chronic Pot Smoking Affects Brain Chemistry, Scans Show 2Health News:Joint Replacement Risks Rise at Less Experienced Hospitals 2Health News:Your attention please: 'Rewarding' objects can't be ignored 2Health News:Your attention please: 'Rewarding' objects can't be ignored 3Health News:For Gay Men, Serious Relationships Still Harbor Risks for HIV 2Health News:Mammary gland development of blueberry-fed lab animals studied 2
22 mm. Plastic, methylmethacrylate, lightweight. Supplied sterile....
Designed to insert eye spheres using spring loaded plunger. Polished finish. Overall length: 125 mm, 4.9 inches....
Size: Large. 24.50 mm by 26.00 mm. Clear lucite. Supplied sterile....
... Size: 2.3 x 6.4 x 80 ... Sponge II line designed by Harvey ... is a closed cell sponge which ... soft with rounded edges to minimize ...
Medicine Products: